| Factor Information | |
|---|---|
| Data ID | 2841 |
| Factor | relationship between fibrosis index and EF (ventricular ejection fraction) |
| Description | The fibrosis index correlated with end-diastolic volume index (r=0.60; P<0.001) and ventricular ejection fraction (r=-0.53; P<0.001) but not with age or oxygen saturation in patients who were cyanotic. |
| Biomarker | NA |
| Classification | Z (combined factor - combined factor) |
| Association | |
|---|---|
| Application | risk assessment |
| Objective | We sought to apply this method for detection and quantification of fibrosis in patients with ACHD. |
| p Value | <0.001 |
| Conclusion | The fibrosis index correlated with end-diastolic volume index (r=0.60; P<0.001) and ventricular ejection fraction (r=-0.53; P<0.001) but not with age or oxygen saturation in patients who were cyanotic. |
| Risk Factor | risk factor(article mentioned) |
| CHD Type | |
|---|---|
| ID | 148 |
| CHD Type | NA |
| CHD Subtype | NA |
| Reference | |
|---|---|
| PMID | 20855860 |
| Year | 2010 |
| Title | Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease |
| Sample | ||
|---|---|---|
| Population | Adults | |
| Source | MRI | |
| Region | Oregon, USA | |
| Method | patients with ACHD (n=50) were studied with cardiac MRI to quantify systemic ventricular volume and function and diffuse fibrosis. | |
| Race | North America | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | ACHD(Treatment) | N/A(Control) |
| Number | 50 | N/A |
| Age | 37±12 years | N/A |
| Gender (Male: Female) | 30:20 | N/A |
| Marker Level | r=-0.53 | N/A |
